Prostate Cancer Clinical Trial

Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer

Summary

RATIONALE: A low-fat, high-fiber diet that includes soy protein may prevent disease progression in patients with hormone-refractory prostate cancer. Nutrition counseling may help motivate patients to follow this diet.

PURPOSE: Randomized phase I trial to study the effectiveness of behavior-based dietary interventions, such as receiving nutrition counseling, in helping patients who have hormone-refractory prostate cancer follow a low-fat, high-fiber, soy-supplemented diet.

View Full Description

Full Description

OBJECTIVES:

Determine whether a behavior-based dietary intervention can motivate patients with hormone-refractory prostate cancer to adopt and maintain a dietary pattern that includes < 20% of energy from fat, > 25 g of fiber, and 80 g of soy protein powder.
Compare bioavailable levels of testosterone in patients treated with a behavior-based dietary intervention vs observation only.
Determine whether this dietary intervention decreases or stabilizes a rising serum prostate-specific antigen level in these patients.
Determine whether this dietary intervention improves disease-specific survival, mediated by reduced bioavailable levels of testosterone, in these patients.
Determine the impact of a positive intervention outcome on androgen receptors in patients treated with this dietary intervention.

OUTLINE: This is a randomized, controlled, pilot, multicenter study. Patients are randomized to 1 of 2 treatment arms.

All patients receive nutritional counseling on a healthy diet. Patients also keep a food diary during study participation.

Arm I (dietary intervention): Patients receive dietary intervention comprising nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52. Treatment continues in the absence of disease progression or unacceptable toxicity.
Arm II (observation): Patients undergo observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.

PROJECTED ACCRUAL: A total of 92 patients (46 per treatment arm) will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the prostate

No small cell component

No histologically confirmed and/or demonstrable metastatic or locally recurrent disease by bone scan, chest x-ray, computed tomography (CT) scan, or transrectal ultrasound

No clinical symptoms within the past 90 days

Documented biochemical failure after radical prostatectomy

Prostate-specific antigen must have initially nadired to an undetectable level (< 0.1 ng/mL) after prostatectomy AND is currently rising (0.3-40.0 ng/mL)
Serum testosterone > 100 ng/dL

PATIENT CHARACTERISTICS:

Age

Any age

Performance status

Zubrod 0-1

Life expectancy

At least 1 year

Hematopoietic

Not specified

Hepatic

Not specified

Renal

Not specified

Other

No known allergic reactions to milk or soy products

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

More than 1 year since prior chemotherapy

Endocrine therapy

More than 1 year since prior hormonal therapy

Radiotherapy

Not specified

Surgery

See Disease Characteristics

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

56

Study ID:

NCT00082732

Recruitment Status:

Completed

Sponsor:

M.D. Anderson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Texas - MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

56

Study ID:

NCT00082732

Recruitment Status:

Completed

Sponsor:


M.D. Anderson Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider